KR20100101097A - 프로스타글란딘 활성을 갖는 치환된 사이클로펜탄 - Google Patents

프로스타글란딘 활성을 갖는 치환된 사이클로펜탄 Download PDF

Info

Publication number
KR20100101097A
KR20100101097A KR1020107012599A KR20107012599A KR20100101097A KR 20100101097 A KR20100101097 A KR 20100101097A KR 1020107012599 A KR1020107012599 A KR 1020107012599A KR 20107012599 A KR20107012599 A KR 20107012599A KR 20100101097 A KR20100101097 A KR 20100101097A
Authority
KR
South Korea
Prior art keywords
hydroxy
cyclopentyl
chloro
propyl
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107012599A
Other languages
English (en)
Korean (ko)
Inventor
야리브 돈데
제레미아 에이취. 엔구옌
로버트 엠. 버크
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20100101097(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20100101097A publication Critical patent/KR20100101097A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)
KR1020107012599A 2007-11-09 2008-11-05 프로스타글란딘 활성을 갖는 치환된 사이클로펜탄 Ceased KR20100101097A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98684907P 2007-11-09 2007-11-09
US60/986,849 2007-11-09
US12/265,062 2008-11-05
US12/265,062 US9006464B2 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity

Publications (1)

Publication Number Publication Date
KR20100101097A true KR20100101097A (ko) 2010-09-16

Family

ID=40524829

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107012599A Ceased KR20100101097A (ko) 2007-11-09 2008-11-05 프로스타글란딘 활성을 갖는 치환된 사이클로펜탄

Country Status (21)

Country Link
US (1) US9006464B2 (enExample)
EP (1) EP2217581B1 (enExample)
JP (1) JP2011503089A (enExample)
KR (1) KR20100101097A (enExample)
CN (2) CN101952261B (enExample)
AR (1) AR069228A1 (enExample)
AU (1) AU2008324793B2 (enExample)
BR (1) BRPI0818902A2 (enExample)
CA (1) CA2705150C (enExample)
CL (1) CL2008003332A1 (enExample)
CO (1) CO6280480A2 (enExample)
DK (1) DK2217581T3 (enExample)
ES (1) ES2432058T3 (enExample)
IL (1) IL205604A (enExample)
MX (1) MX2010005105A (enExample)
NZ (1) NZ585517A (enExample)
RU (1) RU2481339C2 (enExample)
TW (1) TWI411438B (enExample)
UA (1) UA99840C2 (enExample)
WO (1) WO2009061811A1 (enExample)
ZA (1) ZA201003304B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP3991734B1 (en) 2019-06-28 2024-11-27 Gurus BioPharm Inc. Agent for the treatment of alopecia and promoting hair growth

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012A (en) * 1850-01-15 Improvement in mowing-machines
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
JPS5623984B2 (enExample) * 1973-04-19 1981-06-03
US4065472A (en) * 1975-09-29 1977-12-27 Pfizer Inc. 5-(2-Carboxythiophen-5-yl)-16-aryloxy-α-tetranor-ω-tetranorprostaglandins
GB1563201A (en) * 1975-11-05 1980-03-19 Shell Int Research Preparation of herbicidally acitve alanine derivatives
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6545045B1 (en) * 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
WO2008094958A1 (en) 2007-02-01 2008-08-07 Allergan, Inc. Thiophene derivatives useful as medicaments for treating ocular hypertension

Also Published As

Publication number Publication date
DK2217581T3 (da) 2013-10-21
ZA201003304B (en) 2014-03-26
EP2217581B1 (en) 2013-07-31
RU2481339C2 (ru) 2013-05-10
CN101952261B (zh) 2013-06-12
TWI411438B (zh) 2013-10-11
WO2009061811A1 (en) 2009-05-14
CL2008003332A1 (es) 2011-08-12
AR069228A1 (es) 2010-01-06
CA2705150A1 (en) 2009-05-14
EP2217581A1 (en) 2010-08-18
CA2705150C (en) 2016-06-14
IL205604A (en) 2014-06-30
IL205604A0 (en) 2010-11-30
US9006464B2 (en) 2015-04-14
US20090124676A1 (en) 2009-05-14
CO6280480A2 (es) 2011-05-20
UA99840C2 (ru) 2012-10-10
WO2009061811A8 (en) 2009-07-02
JP2011503089A (ja) 2011-01-27
AU2008324793B2 (en) 2013-12-05
TW200934500A (en) 2009-08-16
NZ585517A (en) 2012-08-31
CN102977048A (zh) 2013-03-20
BRPI0818902A2 (pt) 2015-05-12
ES2432058T3 (es) 2013-11-29
CN101952261A (zh) 2011-01-19
MX2010005105A (es) 2010-05-27
RU2010122681A (ru) 2011-12-20
AU2008324793A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
AU641412B2 (en) Intraocular pressure reducing 11, 15-diacyl prostaglandins
IE902721A1 (en) "Intraocular pressure reducing 11-acyl prostaglandins"
US9765065B2 (en) Therapeutic substituted cyclopentanes
WO2011091276A1 (en) Therapeutic substituted chlorocyclopentanols
KR20100101097A (ko) 프로스타글란딘 활성을 갖는 치환된 사이클로펜탄
US20080269498A1 (en) Therapeutic substituted lactams
EP2114913B1 (en) Thiophene derivatives useful as ocular hypotensive agents
US20120178798A1 (en) Substituted cyclopentanes having prostaglandin activity
AU2009209330B2 (en) Substituted gamma lactams as therapeutic agents
EP2487153A1 (en) Substituted cyclopentanes having prostaglandin activity
HK1181392A (en) Substituted cyclopentanes having prostaglanding activity
AU2011209770A1 (en) Therapeutically active cyclopentanes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000